You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

Introduction

Despite significant scientific and clinical progress in the understanding and management of T2DM, patient care remains challenging. The approval of novel treatment options with improved safety, tolerability, and efficacy profiles (eg, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors) has expanded the therapeutic armamentarium for T2DM care. With this expanding array of agents, and the introduction of additional fixed-dose combinations, comes substantial challenges for physicians in selecting the most appropriate individualized regimen for their patients with T2DM.

Activities

Modern T2D TV

Steering Committee

In Memory of Professor Stephan Matthaei
  • With great sadness Medscape Education has learnt of the sudden and unexpected death of Professor Stephan Matthaei in early April 2016. Prof Matthaei was an internationally respected diabetologist, the former President and Board member of the German Diabetes Association and the Head of the Diabetes-Zentrum Quakenbrück in Germany. Prof. Matthaei was a member of the Steering Committee for this Advances in Diabetes Management, and was a regular contributor to educational programs on Medscape.

    He will be dearly missed by all the staff at Medscape Education who have had the honor of working with him over the years.
Steering Committee Chair
  • Tina Vilsbøll, MD, DMScTina Vilsbøll, MD, DMSc
    Head of Diabetes Research,
    Gentofte Hospital,
    University of Copenhagen,
    Copenhagen, Denmark
Steering Committee Members
  • Stephen C. Bain, MD, MBBS, FRCPStephen C. Bain, MD, MBBS, FRCP
    Professor of Medicine (Diabetes), Institute of Life Science, Swansea University College of Medicine; Clinical Lead for Diabetes, ABMU Health Board, Swansea, United Kingdom
  • Alice Y.Y. Cheng, MD, FRCPCAlice Y.Y. Cheng, MD, FRCPC
    Endocrinologist, Trillium Health Partners and St Michael's Hospital; Associate Professor, University of Toronto, Toronto, Ontario, Canada
  • Stephan Matthaei, MDStephan Matthaei, MD
    Professor of Medicine, Diabetes Center Quakenbrück, Hannover, Germany
  • Eduard Montanya, MD, PhDEduard Montanya, MD, PhD
    Professor, Department of Clinical Sciences, University of Barcelona; Chief, Department of Diabetes, Bellvitge University Hospital, Barcelona, Spain
  • Richard Pratley, MDRichard Pratley, MD
    Samuel E. Crockett, MD Chair in Diabetes Research; Director, Florida Hospital Diabetes Center; Senior Investigator, Translational Research Institute for Metabolism and Diabetes; Adjunct Professor, Sanford/Burnham Medical Research Institute, Orlando, Florida, USA
Disclaimer: This Clinical Advances is intended for an audience of healthcare professionals located outside the United States.
Supported by an independent educational
grant from
AstraZeneca Global
Polling Question

With which antihyperglycemic drug class do your patients with T2DM most often experience adverse effects that require them to discontinue treatment?
A sulfonylurea (SU)
A thiazolidinedione (TZD)
A meglitinide (MEG)
A dipeptidyl peptidase-4 (DPP-4) inhibitor
A sodium-glucose cotransporter 2 (SGLT2) inhibitor

Related Resources

Downloadable Slide Kit

Disclosures

Steering Committee
Tina Vilsbøll, MD, DMSc

Tina Vilsbøll, MD, DMSc, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Merck & Co., Inc.; Novo Nordisk; Takeda Pharmaceuticals North America, Inc.
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Eli Lilly and Company; Merck & Co., Inc.; Novo Nordisk; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: Novo Nordisk

Stephen C. Bain, MD, MBBS, FRCP

Stephen C. Bain, MD, MBBS, FRCP, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.; Cellnovo; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Merck Sharp & Dohme Corp.; Novo Nordisk; Sanofi
Served as a speaker or a member of a speakers bureau for: Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Merck Sharp & Dohme Corp.; Novo Nordisk; Sanofi
Received grants for clinical research from: Novo Nordisk

Alice Y.Y. Cheng, MD, FRCPC

Alice Y.Y. Cheng, MD, FRCPC, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott Laboratories; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Becton, Dickinson and Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novo Nordisk; Sanofi; SERVIER; Takeda Pharmaceuticals North America, Inc.; Valeant Pharmaceuticals International
Served as a speaker or a member of a speakers bureau for: Abbott Laboratories; AstraZeneca Pharmaceuticals LP; Becton, Dickinson and Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novo Nordisk; Sanofi; Valeant Pharmaceuticals International

Stephan Matthaei, MD

Stephan Matthaei, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott Laboratories; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Merck Sharp & Dohme Corp.; Novo Nordisk; Roche
Served as a speaker or a member of a speakers bureau for: Abbott Laboratories; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Omnia-Med; Roche
Received grants for clinical research from: Roche

Eduard Montanya, MD, PhD

Eduard Montanya, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; GlaxoSmithKline; Intarcia Therapeutics, Inc.; Janssen Pharmaceuticals, Inc.; Novo Nordisk
Served as a speaker or a member of a speakers bureau for: Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Novo Nordisk

Richard Pratley, MD

Richard Pratley, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Gilead Sciences, Inc.; GlaxoSmithKline; Hanmi Pharmaceuticals Co., Ltd.; Merck & Co., Inc.; Novo Nordisk; Sanofi; Takeda Pharmaceuticals North America, Inc.
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Novo Nordisk
Received grants for clinical research from: Eli Lilly and Company; Gilead Sciences, Inc.; Merck & Co., Inc.; Novo Nordisk; Sanofi; Takeda Pharmaceuticals North America, Inc.
Other: Received honoraria from: Novo Nordisk